Author

T. Rothenburger

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 4 Pharmacology & Toxicology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Organism:human· 6 Assay:bulk RNA-seq· 4 Research Focus:host-pathogen & immune response· 4 Research Focus:drug response / drug discovery· 3 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Research Focus:benchmarking· 1

Frequent Co-Authors

J. Cinatl· 7 shared M. N. Wass· 7 shared D. Bojkova· 6 shared M. Michaelis· 6 shared S. Ciesek· 5 shared F. Rothweiler· 3 shared J. D. Kandler· 3 shared M. Bechtel· 3 shared

Activity by Year

2019-2022 · peak 5/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

7 shared papersMicrobiology

J. Cinatl

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

Repurposing of the antibiotic nitroxoline for the treatment of mpox

D. Bojkova, N. Zoeller, M. Tietgen, K. Steinhorst, M. Bechtel, T. Rothenburger, J. D. Kandler, J. Schneider, V. M. Corman, S. Ciesek, H. F. Rabenau, M. N. Wass, S. Kippenberger, S. Göttig, M. Michaelis, J. Cinatl

This study shows nitroxoline, an antibiotic, inhibits mpox virus replication and remains effective against tecovirimat-resistant strains, suggesting it as a repurposing candidate for mpox treatment.

bioRxiv · Dec 29, 2022Microbiology

Omicron-induced interferon signalling prevents influenza A virus infection

D. Bojkova, M. Bechtel, T. Rothenburger, J. D. Kandler, L. Hayes, R. Olmer, U. Martin, D. Jonigk, S. Ciesek, M. N. Wass, M. Michaelis, J. Cinatl

This study shows Omicron variants induce interferon responses in human cells, protecting against influenza A virus super-infection, while Delta does not.

bioRxiv · Sep 6, 2022 · PreprintMicrobiology

Synergism of interferon-beta with antiviral drugs against SARS-CoV-2 variants

D. Bojkova, R. Stack, T. Rothenburger, J. D. Kandler, S. Ciesek, M. N. Wass, M. Michaelis, J. Cinatl

This study evaluates the antiviral efficacy of interferon-beta combined with antiviral drugs against SARS-CoV-2 variants, finding synergistic effects with certain drugs against specific variants.

bioRxiv · Jul 22, 2022Microbiology

Identification of novel antiviral drug candidates using an optimized SARS-CoV-2 phenotypic screening platform

D. Bojkova, P. Reus, L. Panosch, M. Bechtel, T. Rothenburger, J. Kandler, A. Pfeiffer, J. U. Wagner, M. Shumliakivska, S. Dimmeler, R. Olmer, U. Martin, F. Vondran, T. Toptan, F. Rothweiler, , J. Cinatl

This study develops a phenotypic screening platform using caspase 3/7 activity to identify antiviral compounds against SARS-CoV-2, including novel candidates and combinations.

bioRxiv · Jul 17, 2022Pharmacology & Toxicology

SARS-CoV-2 Omicron variant virus isolates are highly sensitive to interferon treatment

D. Bojkova, T. Rothenburger, S. Ciesek, M. N. Wass, M. Michaelis, J. Cinatl

This study shows that SARS-CoV-2 Omicron variants are more sensitive to interferon treatment than Delta variants, suggesting interferons could be effective therapies for Omicron infections.

bioRxiv · Jan 20, 2022Microbiology

Differences between intrinsic and acquired nucleoside analogue resistance in acute myeloid leukaemia cells

T. Rothenburger, D. Thomas, Y. Schreiber, P. R. Wratil, T. Pflantz, K. Knecht, K. Digianantonio, J. Temple, C. Schneider, H.-M. Baldauf, K.-M. McLaughlin, F. Rothweiler, B. Bilen, S. Farmand, D. Bojkova, , J. Cinatl

This study identifies intrinsic and acquired resistance mechanisms to CNDAC and related nucleoside analogues in AML cells, showing distinct roles of SAMHD1 and DCK.

bioRxiv · Jul 19, 2021Pharmacology & Toxicology

SAMHD1 is a key regulator of the lineage-specific response of acute lymphoblastic leukaemias to nelarabine

T. Rothenburger, K.-M. McLaughlin, T. Herold, C. Schneider, T. Oellerich, F. Rothweiler, A. Feber, T. R. Fenton, M. N. Wass, O. Keppler, M. N. Michaelis, J. Cinatl

This study identifies SAMHD1 as a key regulator of nelarabine response in acute lymphoblastic leukaemias, showing lineage-specific differences in SAMHD1 expression and methylation.

bioRxiv · Dec 3, 2019Pharmacology & Toxicology